BofA Securities Reiterates Buy Rating on Sarepta (SRPT); Top SMID Biotech Pick for 1st-Half
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $187.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) naming it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
